After investing huge sums of money, some pharmaceutical companies began to experience "dyspepsia"

Recently, Yunnan Baiyao released its third quarterly report, showing that the company achieved revenue of 28.
363 billion yuan in the first three quarters, a year-on-year increase of 18.
52%; realized net profit of 2.
451 billion yuan, a year-on-year decrease of 42.
38%, deducting non-parent net profit of 2.
931 billion yuan, a year-on-year decrease of 7.
96%
.
It is understood that this is the first time that Yunnan Baiyao has experienced a year-on-year decline in net profit in the first three quarters since its listing
.
In this regard, industry analysts believe that one of the main reasons for Yunnan Baiyao’s increase in revenue and lower profits is due to the increase in the company’s floating losses in stocks.
Changes
.
In other words, Yunnan Baiyao stocks lost 1.
555 billion
.
In response to this situation, on October 28, people from the Securities Department of Yunnan Baiyao said that the company will gradually optimize its structure and gradually withdraw from securities investment
.
At present, the position has been lowered, and the investment target has been treated very cautiously
.
In fact, due to the difficulty, time-consuming, labor-intensive, and costly research and development of new drugs, many pharmaceutical companies have been vigorously making new investment arrangements in order to increase corporate operating profits in recent years
.
In addition to Yunnan Baiyao, Fosun Pharma has also adopted investment as a long-term business strategy
.
It is reported that relying on investment income, Fosun Pharma's asset scale has increased from 16.
82 billion yuan to 88.
479 billion yuan in the past ten years, an increase of 4.
26 times; in the past three years, its investment income was 1.
815 billion yuan, 3.
565 billion yuan, and 2.
284 billion yuan.
Yuan, accounting for 60%, 95.
21%, and 57.
95% of net profit respectively
.
The huge capital scale, over a hundred mergers and acquisitions, and a relatively long-term investment strategy have made it dubbed the title of "PE in the pharmaceutical industry" in the industry
.
But this year, Fosun Pharma has changed from "buying, buying," to "selling, selling"
.
In April, the controlled Chancheng Hospital was completely transferred; in May, the controlling Taizhou Zhedong Medical Care Investment (its main asset is the Taizhou Zhedong Hospital under construction) was transferred 75% of its shares; in August, it also transferred to Tianjin Jinyao transferred a total of 25.
0011% of its shares in Tianjin Pharmaceutical
.
In October, Fosun Pharma announced again that it planned to transfer its 29.
02% equity of Yaneng Biosciences and 100% equity of Jinshi Medical Inspection Institute to the buyer Yaneng Bioscience for approximately 1.
596 billion yuan
.
It is worth noting that the reasons for the sale of the above assets of Fosun Pharma are actually the same, mainly for optimizing assets, focusing on the main business, supplementing operating funds, and returning interest-bearing debts
.
It is reported that these four sales are expected to return more than 4 billion yuan in funds
.
In general, it is normal for pharmaceutical companies to carry out investment activities in the industry
.
But at the same time of diversified development, the industry believes that the main business should not be forgotten
.
It is reported that Yunnan Baiyao, after "stocking in stocks," each business sector encountered troubles with performance growth, which led to a decline in its overall gross profit margin
.
In particular, the revenue of its traditional pharmaceuticals sector has dropped from 26% in 2014 to 15% in 2019, and its sales have also fallen from 5 billion yuan to 4.
4 billion yuan
.
However, from the perspective of pharmaceutical companies currently focusing on their main businesses and optimizing their development strategies, in the future, pharmaceutical companies will continue to focus on business strategies and innovative R&D to enhance their core competitiveness and expand their performance
.